Feature | Molecular Imaging | July 06, 2016 | Melinda Taschetta-Millane

Highlights from SNMMI

I recently attended the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in San Diego. This year’s meeting included a celebration of the 40th anniversary of FDG, a radiopharmaceutical used in the medical imaging modality positron emission tomography (PET) that has had a pervasive impact on molecular imaging. At the opening plenary session, the Henry Wagner Lecture was given by Joanna Fowler, Ph.D., Brookhaven National Laboratory, on “Designing and Synthesizing FDG for the First Human Studies in 1976.” Signage throughout the convention center featured FDG pioneers and quotes on FDG by past presidents. 

A new “Highlight Country” program was launched this year as well. Japan was the featured country, and had significant contributions to the meeting and to the field of nuclear medicine and molecular imaging. Jun Hatazawa, M.D., Ph.D., president of the Japanese Society of Nuclear Medicine, gave a presentation on the state of nuclear medicine in Japan. Top abstracts for each of the 50 countries participating in the meeting were recognized with awards as well.

SNMMI launched a new fellowship program to recognize distinguished service to the society, as well as exceptional achievement in the field of nuclear medicine and molecular imaging. The Fellowship is recognized with the designation FSNMMI. Selection will be based on documented excellence in volunteer service to the society and at least one of three areas: excellence in scientific discovery and innovation; educational efforts in nuclear medicine and molecular imaging; or clinical practice of nuclear medicine and molecular imaging. All past SNMMI presidents were granted Fellowship.

This year’s Image of the Year was awarded to a German team of researchers from the University Hospital of Cologne; the Jülich Research Center; and the German Center for Neurodegenerative Diseases. Measuring tau deposits using the novel radiotracer18F-AV-1451 (18F-T807), in conjunction with 11C-PiB to measure amyloid plaques and 18F-FDG to measure regional neurodegeneration, offers new insight into the neurodegenerative characteristics of Alzheimer’s disease and shows that tau pathology may be an instrumental target for disease-modifying strategies. More information on this can be found at www.itnonline.com.

On the exhibit hall floor, many new products were introduced, including:

•     Siemens Healthineers highlighted a new release of its syngo.via for molecular imaging software. The company also featured a new mobile configuration of its Biograph Horizon positron emission tomography/computed tomography (PET/CT) system.

•     MIM Software Inc. announced that it received 510(k) U.S. Food and Drug Administration (FDA) clearance to market full MIM products running on tablets through thin client technology such as Citrix; and

•    MEDraysintell displayed its series of market reports and directories. The reports contain over 1,800 pages of intelligence covering nuclear medicine, cyclotrons, brachytherapy and proton therapy.

 

Next year’s meeting will take place June 10–14 in Denver, Colo.

Related Content

Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
The Siemens Biograph Vision PET-CT system was released in mid-2018.

The Siemens Biograph Vision PET-CT system was released in mid-2018.

Feature | Nuclear Imaging | September 07, 2018 | By Dave Fornell
Nuclear imaging technology for both single photon emission computed tomography (SPECT) and positron emission tomography...
Abnormal Protein Concentrations Found in Brains of Military Personnel With Suspected CTE

Researchers are using the tracer, which is injected into a patient, then seen with a PET scan, to see if it is possible to diagnose chronic traumatic encephalopathy in living patients. In this image, warmer colors indicate a higher concentration of the tracer, which binds to abnormal proteins in the brain. Credit UCLA Health.

News | PET Imaging | August 24, 2018
August 24, 2018 — In a small study of
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...